Merck & Co., Inc. vs STMicroelectronics NV — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while STMicroelectronics NV trades at $52.06 (market cap $48.14B). The key difference: Merck & Co., Inc. is far larger — about 7.3× STMicroelectronics NV's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and STMicroelectronics NV for 64 Days on average.
| MRK | STM | |
|---|---|---|
Market Cap | $351.28B | $48.14B |
Volume | 7,969,665 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $156.43 | $79.91 |
52-Week Low | $82.49 | $21.20 |
Typical Hold Time | 98 Days | 64 Days |
Enterprise Value | $398.04B | $45.66B |
Dividend Yield | 2.39% | 0.68% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
STM trades at $52.71, down 6.18% on the day, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS beat ($0.31 vs. $0.26 expected) but missed in Q4 2025 and Q1 2026. Revenue declined from $16.1B in 2022 to $11.8B in 2025, with net income margin turning negative at -0.39% in 2026. Analyst consensus remains positive with a $77.31 price target (51.72% buy ratings), supported by strong AI data-center revenue projections exceeding $2B by 2027 (Reuters, 2026-09-09).
STM faces near-term profitability challenges but offers long-term growth potential in AI and automotive semiconductors. Key risks include execution on margin recovery and macroeconomic volatility. The stock trades at a premium P/E of 101.49, requiring sustained earnings acceleration to justify valuation. Institutional sentiment is cautiously optimistic given the 46% upside to consensus target.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →